Status:
RECRUITING
IMmunotherapy: Prospective Assessment of Cannabis Treatment in Cancer
Lead Sponsor:
State University of New York at Buffalo
Collaborating Sponsors:
Thomas Jefferson University
Oregon Health and Science University
Conditions:
Cancer
Eligibility:
All Genders
21+ years
Brief Summary
The purpose of this research is to assess how patients with cancer being treated with Immune Checkpoint Inhibitors (ICI) manage symptoms related to cancer and/or its treatment. Patients use a variety ...
Detailed Description
Immunotherapy:Prospective Assessment of Cannabis Treatment in Cancer (IMPACT-C) is an observational study to assess the side effect of cancer patients going through immunotherapy treatments. The inves...
Eligibility Criteria
Inclusion
- adult age of 21 years or older
- cancer diagnosis and planning or using immunotherapy treatment,
- pain and spend less than 50% in bed or chair
- fluent in english language
Exclusion
- use synthetic cannabis or only use Cannabidiol (CBD)
- non users but used in the past 3 months
- prior immunotherapy, Patients receiving immunosuppressants or organ transplant recipients.
- Patients within 6 months of Hospice care.
- Pain that limits movement to more than 50% of their day in bed or chair
Key Trial Info
Start Date :
January 2 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT06206941
Start Date
January 2 2025
End Date
December 31 2027
Last Update
October 31 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Oregon Health and Science University
Portland, Oregon, United States, 97239
2
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107